Trends in Epidemiology and Outcome of Small Cell Lung Cancer over 10 Years at Tertiary Cancer Care Center in Iran.

Epidemiology Small Cell Lung Carcinoma Survival

Journal

Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 28 11 2022
accepted: 11 09 2023
medline: 1 4 2023
pubmed: 1 4 2023
entrez: 23 8 2024
Statut: ppublish

Résumé

Lung cancer is the leading cause of cancer death. Among different lung cancer histopathologies, small cell lung cancer (SCLC) has been known to be the most aggressive and lethal nature. This study analyzed the epidemiological characteristics, outcomes, and trends of SCLC at a tertiary cancer care center in Iran. Retrospectively collected demographic characteristics and survival outcome data on histologically proven SCLC patients during 2009-2019 at the National Research Institute of Tuberculosis and Lung Disease (NRITLD) were reviewed. In a study of 334 SCLC patients, there were more male patients than female, with a ratio of 2.5 to 1, and the mean age at diagnosis was 58.36 years. While gender distribution and smoking status among women remained consistent over the study period, there was a significant increase in male smokers (P<0.001). Female patients were diagnosed at younger age and had a significantly lower proportion of smokers compared to males (P<0.016). The mean and median overall survival were 10.9 and 8.2 months, with one-, two-, and three-year survival rates of 21%, 10%, and 3% respectively. Younger patients and females had significantly higher survival rates. In both uni/multivariate analyses, only age < 58 years and female gender were significantly associated with longer survival. The relatively unchanged trend of SCLC in our series suggests that further research on prevention strategies especially smoking cessation, early detection, and new treatment options is urgently required.

Sections du résumé

Background UNASSIGNED
Lung cancer is the leading cause of cancer death. Among different lung cancer histopathologies, small cell lung cancer (SCLC) has been known to be the most aggressive and lethal nature. This study analyzed the epidemiological characteristics, outcomes, and trends of SCLC at a tertiary cancer care center in Iran.
Materials and Methods UNASSIGNED
Retrospectively collected demographic characteristics and survival outcome data on histologically proven SCLC patients during 2009-2019 at the National Research Institute of Tuberculosis and Lung Disease (NRITLD) were reviewed.
Results UNASSIGNED
In a study of 334 SCLC patients, there were more male patients than female, with a ratio of 2.5 to 1, and the mean age at diagnosis was 58.36 years. While gender distribution and smoking status among women remained consistent over the study period, there was a significant increase in male smokers (P<0.001). Female patients were diagnosed at younger age and had a significantly lower proportion of smokers compared to males (P<0.016). The mean and median overall survival were 10.9 and 8.2 months, with one-, two-, and three-year survival rates of 21%, 10%, and 3% respectively. Younger patients and females had significantly higher survival rates. In both uni/multivariate analyses, only age < 58 years and female gender were significantly associated with longer survival.
Conclusion UNASSIGNED
The relatively unchanged trend of SCLC in our series suggests that further research on prevention strategies especially smoking cessation, early detection, and new treatment options is urgently required.

Identifiants

pubmed: 39176146
pii: Tanaffos-22-411
pmc: PMC11338514

Types de publication

Journal Article

Langues

eng

Pagination

411-417

Informations de copyright

Copyright© 2023 National Research Institute of Tuberculosis and Lung Disease.

Auteurs

Sharareh Seifi (S)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Ghazal Fakhrai (G)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Zahra Esfahani-Monfared (Z)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Adnan Khosravi (A)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Atefeh Abedini (A)

Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Babak Salimi (B)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Maryam Seifi (M)

Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran.

Mahdi Tabarraee (M)

Department of Adult Hematology & Oncology, School of Medicine, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mahmoud Dehghani Ghorbi (M)

Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.

Classifications MeSH